Century Therapeutics, Inc. (IPSC) Earnings History

Century Therapeutics, Inc. - Q3 2025 Earnings

Filed at: Nov 12, 2025, 7:00 PM EST|Read from source

EXECUTIVE SUMMARY

Century Therapeutics reported a net loss for Q3 2025, with a decrease in collaboration revenue compared to the prior year's nine-month period. The company is prioritizing its beta islet cell program for Type 1 diabetes and its CNTY-308 program, with an estimated cash runway into Q4 2027.

POSITIVE HIGHLIGHTS

  • •

    Estimated cash runway into Q4 2027.

    positive
  • •

    Announced lead beta islet program, CNTY-813, for Type 1 diabetes with IND-enabling studies to initiate by year-end 2025 and IND submission planned in 2026.

    positive
  • •

    CNTY-308 advancing through IND-enabling studies with clinical study initiation planned in 2026.

    positive
  • •

    Initial clinical data from CARAMEL IST for CNTY-101 expected in December 2025.

    positive

CONCERNS & RISKS

  • •

    Collaboration revenue decreased from $791 thousand in Q3 2024 to $0 for Q3 2025, and from $2.4 million in the nine months ended September 30, 2024, to $109.2 million for the same period in 2025.

    negative
  • •

    Net loss increased to $34.4 million in Q3 2025 from $31.2 million in Q3 2024.

    negative
  • •

    Impairment of long-lived assets of $6.8 million in Q3 2025.

    attention
  • •

    Cash, cash equivalents, and marketable securities decreased to $132.7 million as of September 30, 2025, from $220.1 million as of December 31, 2024.

    attention

FINANCIAL METRICS

Revenue
Quarterly
$0.00
-100.0%
Prior year: $791.00K
Annual (YTD)
$109.16M
N/A
Prior year: $2.42M
Net Income
Quarterly
$-34.42M
-10.3%
Prior year: $-31.23M
Annual (YTD)
$9.59M
N/A
Prior year: $-90.49M
EPS (Diluted)
Quarterly
$-0.40
-8.1%
Prior year: $-0.37
Operating Income
Quarterly
$-36.12M
-3.9%
Prior year: $-34.79M
Annual (YTD)
$3.38M
N/A
Prior year: $-100.85M
EPS (Basic)
Quarterly
$-0.40
-8.1%
Prior year: $-0.37

MARGIN ANALYSIS

Operating Margin
Current Quarter
-100.0%
Prior Year
-4395.1%
YoY Change
+4295 bps
Net Margin
Current Quarter
-100.0%
Prior Year
-3940.9%
YoY Change
+3841 bps

Margin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.

SPECIAL ITEMS & ADJUSTMENTS

Q3 2025
Impairment of long-lived assets
+$6.763M
Q3 2025
Gain on lease modification
Contributed to decrease in G&A expenses.
+$1.4M
Total Impact
+$8.163M

Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.

MANAGEMENT COMMENTARY

Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); IND-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026.

— Century Therapeutics, Inc., Q3 2025 2025 Earnings Call

CNTY-308 advancing through IND-enabling studies to support planned clinical study initiation in 2026.

— Century Therapeutics, Inc., Q3 2025 2025 Earnings Call

Estimated cash runway into 4Q 2027.

— Century Therapeutics, Inc., Q3 2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.